Harvard Bioscience, Inc. Q3 2025 Earnings Recap

Harvard Bioscience achieved strong operational advancements in Q3 2025, reporting revenues of $20.6 million and improved margins, while demonstrating robust customer engagement and a growing backlog ahead of the fourth quarter.

Key Takeaways

• Revenue of $20.6 million met guidance expectations, rebounding from a historically soft period.
• Gross margin expanded to 58.4%, reflecting improved operational efficiency and a favorable product mix.
• Customer order growth marked a year-over-year increase for the first time in over a year, driven by heightened demand and a growing product backlog.
• Successful launch of the Incub8 Multiwell System bolstered market presence and initial customer feedback has been positive.
• Strategic advances in capital structure highlight ongoing debt refinancing efforts, set for completion in Q4 2025.